Navigation Links
GlaxoSmithKline and Genmab Present Positive Phase II Results With,ofatumumab in Patients With Rheumatoid Arthritis (RA)

ell as improvements in other disease-activity measures.

In the subgroup of patients receiving concomitant stable doses of methotrexate, comprising 178 patients, results across the three dose levels of ofatumumab studied showed that an ACR20 response was obtained by 42% (p=0.006), 56% (p<0.001) and 50% (p=0.001) of patients in the 300 mg, 700 mg and 1000 mg dose groups, respectively compared to 16% in the placebo group. An ACR50 response was obtained by 21%, 26% and 26% of patients receiving the varying doses of ofatumumab, with 8%, 2% and 5% obtaining an ACR70 response. The corresponding responses for the placebo group were 7% and 0%.

At 24 weeks, the patients' immune responses to study medication (ofatumumab or placebo) were also evaluated by testing for the presence of human anti-human antibodies (HAHAs). All patients tested negative at 24 weeks.

Overall, 72% (300 mg p<0.001; 700 mg p=0.001; 1000 mg p=0.001) of patients treated with each of the ofatumumab doses experienced at least a moderate (moderate or good) EULAR response compared to 40% of patients receiving placebo at week 24.

The data also showed that ofatumumab appeared well tolerated, with no increased frequency of serious infections. Approximately half of the adverse events occurred on infusion days (51%) with the most frequently reported being mild or moderate (CTC grade 1-2 events), including throat irritation, dyspnoea and rash.

"These results represent another positive milestone in the development of ofatumumab. They will enable us to progress development in the rheumatoid arthritis (RA) indication and help bring this potentially important treatment to patients suffering from this often painful and debilitating condition," commented Dr. Kathy Rouan, Vice President, Research and Development, GlaxoSmithKline.

"The level of response of patients in the study illustrates the potential of ofatumumab in the treatment of RA and we hope to see similar results in the P
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
2. New Data on Genmab and GlaxoSmithKlines Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR
3. Genmabs HuMax-EGFr Shows Broad Potential in Cancer Treatment
4. The Past, Present and Future of HLA Typing
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
10. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
11. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:5/9/2008)...Fifth International Phase III Study Shows Positive... Data -, NUTLEY, N.J., May 9 /- Roc...-year Phase III study showing that ACTEMRA(TM),(to...f structural damage to,joints in patients with rhe...ctiveness of an RA treatment. The study also demon...
(Date:5/8/2008)...CLEVELAND, May 8 /- DATATRA...gy and services company focused on global,eClinica...y reported its,operating results for the first qua...1, 2008, revenue decreased,approximately 41% to $2...2,233,000), or $(0.16) per share on both a basic a...
(Date:5/8/2008)...BOSTON, May 8 /- The Cancer Research ...ation,s top cancer centers, is asking,303 million ...onating $1 to,cancer research efforts this Mother,... the "Infinite Power of One(TM)" has two key goals... into their own hands by,joining together to exerc...
(Date:5/8/2008)...cacy and safety data support potential of asenapin...ia and bipolar I disorder, WASHINGTON, May 8 /PRN...(NYSE: SGP ) today announced that an overview of ... was presented at the 161st Annual Meeting of the,...C., May 3-8. Data from,the studies, involving pati...
Breaking Medicine Technology:New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 3New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 5DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 2World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 3World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 4World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7Cleaner Air Leads to Healthier Lungs 7677 1Cleaner Air Leads to Healthier Lungs 7677 2Cleaner Air Leads to Healthier Lungs 7677 3GNC Franchising Expected to Grow Through 2008 7673 1GNC Franchising Expected to Grow Through 2008 7673 2Ventas Grants Stock Awards to Promote Long Term Retention and Reward Performance 7669 1Ventas Grants Stock Awards to Promote Long Term Retention and Reward Performance 7669 2Ventas Grants Stock Awards to Promote Long Term Retention and Reward Performance 7669 3Ventas Grants Stock Awards to Promote Long Term Retention and Reward Performance 7669 4Medical Industry Offers Food Ingredient Companies More Than One Billion Reasons to Think Healthy 7665 1Medical Industry Offers Food Ingredient Companies More Than One Billion Reasons to Think Healthy 7665 2
...n 12, 2007 - Critical,Therapeutics, Inc. (Nasdaq: ... a pivotal Phase III clinical trial of ZYFLO CR(TM...2007 issue of the,Journal of Asthma. ZYFLO CR was ...(FDA) on May 30, 2007. Critical Therapeutics,toge..., expects to,begin marketing ZYFLO CR in the U.S. ...
... Efficacy with Either Every,Two Weeksn or Monthly ...CET - New pivotal data,(RAPID 1 and RAPID 2) prese...gy (EULAR) show that Cimzia (certolizumab pegol), ...th methotrexate,therapy has a rapid and significan...ive rheumatoid arthritis (RA) compared with,methot...
Other Medicine Technology:Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 2Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 3Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 5Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 2Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 3Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 4Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 5Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 6Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 7Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 8
(Date:5/12/2008)...2 /PRNewswire-FirstCall/ - The Westaim Corporation...March 31, 2008, it,recorded a net loss of $6.9 mil...lion. In the same quarter last year, the company r... share, on revenues of $6.1 million., Income from...arter,compared to $1.9 million in the same period ...
(Date:5/12/2008)...., May 12 /PRNewswire-FirstCall/ -- (Nasdaq: WHRT,...r the "Corporation") announced,that the Toronto St...ing it,is reviewing the eligibility for continued ...art under sections 709 and 710(a) of the TSX Compa...nancial condition and,operating results, more spec...
(Date:5/12/2008)... 12 /PRNewswire-FirstCall/ -- Allied Healthcare Pr...its net income for the third,quarter ending March ... or,4 cents per share, to about $100,000 in the cu...e third quarter increased by about $240,000 compar..., higher material and labor costs,this fiscal year...
(Date:5/12/2008)... May 12 /Xinhua-PRNewswire-FirstCall/ -- China Yin...) ("China Yingxia" or "the,Company"), a leading pr...e,development, manufacture and distribution of org...ersonal care products in the People,s Republic,of ...onference call,Friday, May 16, 2008, at 10:00 a.m...
Breaking Medicine News(10 mins):Health News:Westaim announces 2008 first quarter results 2Health News:Westaim announces 2008 first quarter results 3Health News:WorldHeart Notified of TSX Delisting Review 2Health News:Allied Healthcare Net Falls on Manufacturing Delays 2Health News:Allied Healthcare Net Falls on Manufacturing Delays 3Health News:Allied Healthcare Net Falls on Manufacturing Delays 4Health News:Allied Healthcare Net Falls on Manufacturing Delays 5Health News:China Yingxia International, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2
...ation system that can perform a variety of tests o...icket captain Dilip Vengsarkar here Tuesday//. Pri...otherapists to accurately measure the performance,...els of sportspersons. "The heavy emphasis on Ind...
...ded for consumption without a break is threatening...ve pill//. The pill, named Anya, manufactured by W...th Canada, which will enable women to give a merry...e in neither United States nor Canada, Anya is und...
...he first province in Canada to start accepting tra...failure//. The provincial agency in charge of org...guidelines that allowed accepting donation after c...ould potentially expand the potential donor pool b...
...Sainsbury's are negotiating details about running ...ie Oliver//, to promote the dying concept of famil.... This would mark a controversial departure for g...ts tie-up with a commercial brand. The health depa...
Other Medicine News:Health News:Ontario Addresses Shortage of Transplant Organs 2
The NIAGARA Thermal Retention System (TRS) maintains the temperature of prewarmed irrigation fluid continuously as it is delivered through the Corson®, Surgiflex® WAVE™, or Surgiflex D
...ace the eyeglasses in the EZ Meter and press the m...isplay the measurement results on its large color ... printout makes this the ideal instrument for use ...ion to being extremely easy-to-use, the EZ-200 is ...
Simple, Effective Laparoscopic Irrigation Pumps from the Market Leader
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump.
Medicine Products: